Compare KPTI & MCHX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KPTI | MCHX |
|---|---|---|
| Founded | 2008 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.6M | 62.3M |
| IPO Year | 2013 | 2003 |
| Metric | KPTI | MCHX |
|---|---|---|
| Price | $7.90 | $1.40 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $17.50 | N/A |
| AVG Volume (30 Days) | ★ 792.1K | 12.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 52.17 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $146,067,000.00 | $90,291,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $46.62 | $6.70 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 0.57 | N/A |
| 52 Week Low | $3.51 | $1.26 |
| 52 Week High | $10.99 | $2.30 |
| Indicator | KPTI | MCHX |
|---|---|---|
| Relative Strength Index (RSI) | 42.19 | 31.92 |
| Support Level | $5.60 | $1.35 |
| Resistance Level | $7.81 | $1.76 |
| Average True Range (ATR) | 0.76 | 0.05 |
| MACD | -0.24 | -0.00 |
| Stochastic Oscillator | 2.84 | 25.00 |
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
Marchex Inc provides AI-based conversational intelligence and analytics solutions that generate insights from customer communications data. The company's products support sales, marketing, and executive teams in analyzing customer interactions across communication channels and informing business decisions. It serves companies operating in business-to-business-to-consumer (B2B2C) markets across multiple industries like automotive, home services, healthcare, real estate, and advertising. The company operates in a single segment: conversational analytics and related solutions. The company generates the majority of revenue from its conversational intelligence product offerings. Geographically, it generates the maximum revenue from the United States.